LY2216684
12849
Phase 3 small_molecule completed
Quick answer
LY2216684 for Major Depressive Disorder is a Phase 3 program (small_molecule) at Eli Lilly and Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly and Company
- Indication
- Major Depressive Disorder
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed